18 results about "Human b cell" patented technology

The present disclosure provides methods of producing and expanding populations of B cells (e.g., human B cells for clinical applications). Such expanded populations can be used to produce B cell vaccines containing B cells that express 4-1BBL and are capable of promoting tumor cell death.

The invention is applicable to the technical field of biotechnology, and particularly relates to a primer composition for amplifying a coding sequence of a human B cell receptor heavy chain CDR3 and application of the primer composition, and two primer groups, namely a first primer group and a second primer group, are designed. The two primers are respectively used as an upstream primer and a downstream primer, and comprise at least one human IGH CDR3 upstream primer and at least one human IGH CDR3 downstream primer. The primers can be respectively combined with nucleic acid of human B cells, and a basis for researching a CDR3 region of a B cell receptor is provided. The first primer group and the second primer group are combined with the nucleic acid of the human B cell, so that the coding sequence of the heavy chain of the human B cell receptor is effectively enriched, part of pseudogenes are contained, the amplification efficiency of the heavy chain CDR3 library of the human B cell receptor can be improved, and the deep research on immune response of the human B cell is promoted.

The present invention provides affinity matured recombinant monoclonal antibodies (mAbs) and fragments that bind specifically to an HLA-E-peptide complex, including HLA-E-VL9 complexes, and. regulate the cytotoxicity effector cell function of NK and / or CD8+ T-cells positive for cell-surface expression of NKG2A (“NKG2A+”). Herein, monoclonal antibodies were recombinant.lv derived from isolated functional HLA-E-VL9-specific mAbs from HLA-E-VL9 peptide-immunized HLA-B transgenic mice and from the naive human B cell repertoire. Such antibodies are capable of regulating effector cell cytotoxicity' and can preferentially recognize HLA-E-VL9 peptide complexes expressed on the surface of tumor cells. The monoclonal antibodies were subject to one or more rounds of affinity 7 maturation. The invention provides methods for using affinity matured HLA-E-VL9 mAbs to modulate NK and / or CD8+T-cell function as part of immunotherapeutic strategies.

A continuous directed evolution platform in human B cell lines (CODE-HB) that recruits and repurposes the inherent B cell somatic hypermutation (SHM) mechanisms to rapidly evolve proteins is described. This approach uses stable, non-immunoglobulin loci within the genomes of human B cell lines for integration of a heterologous gene, such as a gene encoding an antibody or antibody fragment. A B-cell surface display platform for displaying fragment antigen binding domains (Fab) of antibodies is also described, which adapts the CODE-HB platform to rapidly evolve antibody fragments in a continuous manner. Plasmids and kits for carrying out these methods are also described.

The present disclosure provides methods of producing and expanding populations of B cells (e.g., human B cells for clinical applications). Such expanded populations can be used to produce B cell vaccines containing B cells that express 4-1BBL and are capable of promoting tumor cell death.

This text relates to anti-proliferative compounds for combined use and bispecific antibodies targeting BCMA and CD3. Provided herein are methods of treating, preventing, or controlling multiple myeloma using 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile or an enantiomer thereof, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt, and a bispecific antibody that specifically binds to human B cell maturation antigen (BCMA) and human CD3e (CD3) provided herein.

The present disclosure provides a method for producing and expanding a population of B cells (e.g., human B cells for clinical application). This expanded population can be used to produce a B cell vaccine containing B cells that express 4-1BBL and can promote tumor cell death.

Recombinant monoclonal antibodies (mAbs) and fragments that bind specifically to an HLA-E-peptide complex, including HLA-E-VL9 complexes, and regulate the cytotoxicity effector cell function of NK and / or CD8+ T-cells positive for cell-surface expression of NKG2A (“NKG2A+”). Herein, monoclonal antibodies were recombinantly derived from isolated functional HLA-E-VL9-specific mAbs from HLA-E-VL9 peptide-immunized HLA-B transgenic mice and from the naive human B cell repertoire. Such antibodies are capable of regulating effector cell cytotoxicity and can preferentially recognize HLA-E-VL9 peptide complexes expressed on the surface of tumor cells. The invention provides methods for using HLA-E-VL9 m Abs to modulate NK and / or CD8+ T-cell function as part of immunotherapeutic strategies.

The present invention provides affinity matured recombinant monoclonal antibodies (mAbs) and fragments that bind specifically to an HLA-E- peptide complex, including HLA-E-VL9 complexes, and regulate the cytotoxicity effector cell function of NK. Herein, monoclonal antibodies were recombinantly derived from isolated functional HLA-E-VL9-specific mAbs from the naïve human B cell repertoire. Such antibodies are capable of regulating effector cell cytotoxicity and can preferentially recognize HLA-E-VL9 peptide complexes expressed on the surface of tumor cells. The monoclonal antibodies were subject to one or more rounds of affinity maturation. The invention provides methods for using affinity matured HLA-E-VL9 mAbs to modulate NK cell function as part of immunotherapeutic strategies.

The present invention relates to a method of generating a composition comprising cytotoxic T cells (CTLs) that comprise (a) a T cell receptor (TCR) that binds to a first antigen, and (b) a chimeric antigen receptor (CAR) that binds to a second antigen, said method comprising: i) preparing a culture of cells comprising CD3+ T cells derived from human peripheral blood mononuclear cells (PBMCs) obtained from a subject; ii) co-culturing said culture with human B cell lymphoblastoid cells (BLCLs) that have been engineered to express said first antigen; iii) maintaining said co-culture for a time sufficient to induce selective proliferation of CTLs comprising a TCR that binds to said first antigen; iv) transducing the CTLs of said co-culture with a viral vector comprising a nucleic acid sequence encoding a CAR that binds to said second antigen, thereby providing CTLs that comprise (a) a TCR that binds to said first antigen and (b) a CAR that binds to said second antigen; v) culturing the CAR-expressing first-antigen-specific CTLs to allow proliferation of such CTLs; vi) optionally re-culturing said CAR-expressing, first-antigen-specific CTLs one or more times as a co-culture with BLCLs that have been engineered to express said first antigen, thereby further sensitizing said CAR-expressing first-antigen-specific CTLs to said first antigen; and vii) harvesting a composition comprising CTLs that comprise (a) a TCR that binds to said first antigen, and (b) a CAR that binds to said second antigen.

The present invention provides affinity matured recombinant monoclonal antibodies (mAbs) and fragments that bind specifically to an HLA-E- peptide complex, including HLA-E-VL9 complexes, and regulate the cytotoxicity effector cell function of NK. Herein, monoclonal antibodies were recombinantly derived from isolated functional HLA-E-VL9-specific mAbs from the naïve human B cell repertoire. Such antibodies are capable of regulating effector cell cytotoxicity and can preferentially recognize HLA-E-VL9 peptide complexes expressed on the surface of tumor cells. The monoclonal antibodies were subject to one or more rounds of affinity maturation. The invention provides methods for using affinity matured HLA-E-VL9 mAbs to modulate NK cell function as part of immunotherapeutic strategies.

The present disclosure provides methods of producing and expanding populations of B cells (e.g., human B cells for clinical applications). Such expanded populations can be used to produce B cell vaccines containing B cells that express 4-1BBL and are capable of promoting tumor cell death.

Provided herein are humanized immunodeficient mouse comprising human myeloid cells and human lymphoid cells, wherein the human lymphoid cells comprise human B cells that produce circulating immunoglobulin (Ig), for example, physiological levels of human IgG, and wherein the mouse expresses a detectable level of human FLT3L protein and does not express a detectable level of mouse FLT3 protein.

The application discloses a CD40 antibody or antigen binding fragment and application thereof. The CD40 antibody or antigen binding fragment has strong binding capacity with hCD40, can activate a CD40 / CD40L signal transduction pathway and downstream regulation signals thereof, can induce human B cell activation and significantly up-regulate CD95 protein expression, can promote B cell proliferation, can induce human PBMC-derived iDC cell activation and secrete a cytokine IL-12. The CD40 antibody or antigen binding fragment does not have ADCC effect, ADCP effect and CDC effect, can significantly reduce tumor volume / weight without affecting mouse body weight, prolong the survival time of mice, has good drug metabolism kinetics, and can be used for detecting hCD40 expression level and treating tumors.

The invention(s) disclosed herein relate to improved methods for expanding cell populations, particularly B cell populations. The invention further relates comprising improved cell media, compositions thereof, and methods of using such expanded B cells. Wherein a population of cells comprises engineered human B cells, wherein the engineered human B cells comprise a therapeutic protein, whose gene has been inserted into the beta-2M locus.

Provided are compositions and methods that relate to therapy of B cell diseases and include discovery of novel molecular heterogeneity of the signaling component (i.e., CD79) of human B cell antigen receptor (BCR). The method includes co-administering antibodies or antigen binding fragments thereof that specifically bind CD79a and CD79b to provide synergistic therapy of B cell tumors. The method may further include administering an antibody that specifically binds to an immune checkpoint molecule, such as programmed cell death protein 1 (PD-1).

The present disclosure provides antibodies, and fragments thereof, having specificity for human B cell maturation antigen, pharmaceutical compositions thereof, and uses thereof. Also provided are chimeric antigen receptors (CARs) comprising such antibodies or antibody fragments, genetically-modified cells comprising such CARs, pharmaceutical compositions comprising such cells, methods for making such cells, and methods of using such cells for the treatment of disorders and diseases, such as cancer.